ARS Pharmaceuticals Inc - SPRY Earnings per share for the trailing year

Public company logo of ARS Pharma (SPRY)

The successful market launch of Neflo confirms the high qualification of ARS Pharmaceuticals (SPRY) management regarding regulatory matters. The annual growth of basic net income per share (TTM) exhibits volatility, where the value -148.60 represents the current figure. The business relies on production outsourcing to reduce costs, while the modernization of contractor lines allows for the scaling of output volumes without operational pauses.

ars-pharma.com (SPRY): Earnings per share for the last twelve months from 02/11/2024 to 11/14/2026

SPRY (ARS Pharmaceuticals): analytical breakdowns and indicator data

- stock price and consensus target price:
Price ARS Pharmaceuticals, Inc.|SPRY - Analyst Consensus Forecast
- issuer market value details:
Market Value ARS Pharma|SPRY - Enterprise Value
- issuer book value statistics:
Net Asset Value per Share ARS Pharmaceuticals|SPRY - Company Book Value|Market Value to Book Value ars-pharma.com|SPRY - Company Total Assets
- company total debt and liquidity indicators:
Total Debt to Capital ARS Pharmaceuticals|SPRY - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital ars-pharma.com|SPRY - Company Debts|Debts to Net Assets ARS Pharmaceuticals|SPRY - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings ARS Pharmaceuticals|Critical Liquidity Ratio ars-pharma.com
- net income and valuation ratios data:
SPRY - Net Profit|Expected Net Income ARS Pharmaceuticals|SPRY - P/E Multiple|Forward P/E Multiple ARS Corp|SPRY - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation ARS Corp|SPRY - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months ARS Pharmaceuticals|SPRY - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth ars-pharma.com|SPRY - Earnings growth in current year|Expected earnings per share growth for next year ARS Pharmaceuticals
- revenue and sales details:
SPRY - Revenue and Sales Volume|Company Expected Sales Volume ARS Pharma|SPRY - Market Cap to Revenue|Forward P/S Multiple ARS Pharmaceuticals
Initial company analysis:SPRY (ARS Pharma)
Mass-produced product of ARS Corp

This indicator measures the dynamics of net earnings per share over a rolling year, allowing for an assessment of capital scaling rates and expense management efficiency. By analyzing the historical delta of EPS YoY TTM, an investor can see how the optimization of spray logistics reduces delivery costs, which directly converts into profit growth and confirms the fundamental resilience of the ARS Pharmaceuticals business.

Direct competitors

Earnings per share for the trailing year HLN (Haleon)|KVUE: Net earnings per share (EPS TTM)|Verona Pharma Corp - Earnings per share for the trailing year|MENS (Jyong Biotech Limited) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months ligand.com LGND|Earnings per share for the last twelve months Amneal (AMRX)|PRGO (Perrigo Company PLC) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) ALVO (Alvotech S.A.)|Liquidia Technologies - Earnings per share for the last twelve months|Galapagos Corp - Net earnings per share (EPS TTM)|ANIP (ANI Pharmaceuticals) - Earnings per share for the last 12 months|MannKind Corp. (MNKD) - Earnings per share for the last twelve months|Earnings per one share for the last 12 months AMPH (Amphastar Pharmaceuticals, Inc.)|PCRX (Pacira Corp) - Net earnings per share (EPS TTM)|TBPH: Earnings per share for the trailing year|Earnings per share for the last twelve months aquestive.com (AQST)|Net earnings per share (EPS TTM) scPharmaceuticals, Inc. (SCPH)|Earnings per share for the last twelve months tectonictx.com TECX|Earnings per share for the trailing year TNXP|SXTC - Earnings per share for the last twelve months|Net earnings per share for the last four quarters eupraxiapharma.com EPRX|BHST: Net earnings per share (EPS TTM)|EXOZ - Net earnings per share for the last four quarters|ORMP (oramed.com) - Net earnings per share (EPS TTM)|enterabio.com (ENTX) - Net earnings per share for the last four quarters|Net earnings per share (EPS TTM) HYFT|ABVC (ABVC BioPharma Inc) - Earnings per share for the trailing year|Cumberland Pharmaceuticals - Net earnings per share for the last 12 months|quantumbiopharma.com (QNTM) - Net earnings per one share for the last twelve months|FibroGen Inc - Net earnings per share (EPS TTM)|Earnings per share for the trailing year TELO (Telomir Pharmaceuticals Inc)|RANI (Rani Therapeutics Holdings, Inc.) - Net earnings per share for the last 12 months|Net earnings per share for the last 12 months Synergy CHC Corporation|Earnings per share for the last twelve months Rallybio Corp|Lexaria Bioscience (LEXX) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Pulmatrix, Inc. (PULM)|Net earnings per share for the last four quarters Pheton|Earnings per share for the last twelve months Aptorum Group Limited APM|LYRA - Net earnings per share for the last 12 months|IBO: Net earnings per share for the last 12 months|TNFA - Net earnings per share (EPS TTM)|cbdMD Corp (YCBD) - Earnings per share for the last twelve months|Earnings per one share for the last 12 months PRFX (PainReform Limited)|CYTO (Altamira Therapeutics Ltd.) - Net earnings per share (EPS TTM)|Lipella (LIPO) - Net earnings per share for the last four quarters|Net earnings per share (EPS TTM) OPTN|Net earnings per share (EPS TTM) pieris.com (PIRS)|Earnings per share for the last twelve months Procaps Group Corp PROC|Petros Pharmaceuticals Inc - Earnings per share for the last twelve months|Qilian International Corp - Net earnings per share (EPS TTM)|ACELYRIN, Inc. (SLRN) - Net earnings per share for the last 12 months|TFF Pharma (TFFP) - Earnings per share for the last twelve months